70 results
8-K
EX-99.2
IVVD
Invivyd Inc
4 Apr 24
Invivyd Provides PEMGARDATM Launch Update and Announces 2024 Net Product
5:25pm
main phases Product Securing Full Commercial Availability Reimbursement Implementation & Access Deploy national account managers Fully deploy
8-K
EX-99.1
IVVD
Invivyd Inc
28 Mar 24
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
7:05am
healthcare providers have immediate access to medications to treat anaphylaxis and the ability to activate the emergency medical system (EMS … calendar days from the healthcare provider’s awareness of the event, using FDA Form 3500 (for information on how to access this form, see below
8-K
EX-99.3
dx8u0pk
22 Mar 24
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
8:58pm
8-K
EX-99.1
jcekahq
22 Mar 24
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
8:58pm
8-K
EX-99.1
8lnrbuty4 3jzi
9 Feb 24
Index to Consolidated Financial Statements
4:01pm
8-K
EX-99.1
79g1ous zyhjgdogv
8 Jan 24
Other Events
7:12am
8-K
EX-10.1
3hm33m324oyi34m5l
22 Dec 23
Entry into a Material Definitive Agreement
4:53pm
8-K
EX-99.2
nlhzvw
9 Nov 23
Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights
4:10pm
8-K
EX-99.1
ta65s6
9 Nov 23
Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights
4:10pm
DEFA14A
kj2hid1
10 Apr 23
Additional proxy soliciting materials
4:10pm
DEF 14A
q5dncoza7a
10 Apr 23
Definitive proxy
4:07pm
PRE 14A
ywm9f9a k8x7gsrp62
31 Mar 23
Preliminary proxy
4:36pm